Abstract

Ectopic adrenocorticotropic hormone secretion from lung tumors causing Cushing syndrome are associated with high rates of morbidity. Optimal management remains obscure because knowledge is based on rare reports with few patients. To characterize the outcomes of lung neuroendocrine tumors associated with Cushing syndrome. An observational case series review from 1982 to 2020 was conducted in a single institution referral center. Kaplan-Meier analysis estimated disease-free survival (DFS). Participants underwent curative-intent surgery for a lung neuroendocrine tumor causing Cushing syndrome. Lobectomy or pneumonectomy vs sublobar resection. Disease-free survival, disease persistence/recurrence. Of the 68 patients, the median age was 41 years (range, 17-80 years), 42.6% (29 of 68) were male, 81.8% (54 of 66) were White, with a mean follow-up after surgery was 16 months (range, 0.1-341 months). Lobectomy was the most common procedure (48 of 68 [70.6%]), followed by wedge resection (16 of 68 [23.5%]) and segmentectomy (3 of 68 [4.4%]). Video-assisted thoracoscopic surgery was performed in 19 of 68 (27.9%) of patients. Surgical morbidity was 19.1% (13 of 68), and perioperative mortality was 1.5% (1 of 68). Lymph node positivity was 37% (22 of 59) when evaluable. The overall incidence of persistence/recurrence was 16.2% (11 of 68) with a median time to recurrence of 55 months (range, 18-152 months). The median DFS was reached in 12.7 years (0.1-334 months). There were no statistical differences in DFS based on tumor size, stage (8th edition TNM), whether full systematic lymphadenectomy was performed or not, nodal status, or surgical approach. In this case series study, neuroendocrine pulmonary tumors associated with Cushing syndrome had increased nodal metastasis, higher recurrence, and lower DFS than quiescent bronchopulmonary carcinoid tumors, but many patients experienced favorable outcomes. This observation is underscored by the discordance of TNM-stage classifications vs prognosis. Observing no difference in surgical techniques, the implication may be that a lung-sparing approach could suffice. These results may reflect the intrinsic importance of the hormone physiology instead of the carcinoid biologic factors.

Highlights

  • IntroductionBronchopulmonary carcinoid tumors, account for 1% to 2% of lung cancers in the US

  • Pulmonary neuroendocrine tumors, or bronchopulmonary carcinoid tumors, account for 1% to 2% of lung cancers in the US

  • In this case series study, neuroendocrine pulmonary tumors associated with Cushing syndrome had increased nodal metastasis, higher recurrence, and lower disease-free survival (DFS) than quiescent bronchopulmonary carcinoid tumors, but many patients experienced favorable outcomes

Read more

Summary

Introduction

Bronchopulmonary carcinoid tumors, account for 1% to 2% of lung cancers in the US. 90% are typical carcinoid (TC) tumors, and 10% are atypical carcinoid (AC) tumors.. Given the neuroendocrine origin of these tumors, various paraneoplastic syndromes may occur. Cushing syndrome (CS) from ectopic adrenocorticotropic hormone secretion (EAS) is seen in 1% to 6% of carcinoid tumors worldwide, comprising a rare subgroup.. Surgical resection is the standard treatment and is curative in selected patients with CS with EAS bronchial carcinoid tumors.. There are no uniform surgery guidelines, which vary from wedge resection to pneumonectomy to bronchial sleeve resection for central tumors. Surgical resection is the standard treatment and is curative in selected patients with CS with EAS bronchial carcinoid tumors. there are no uniform surgery guidelines, which vary from wedge resection to pneumonectomy to bronchial sleeve resection for central tumors.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call